• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mass spectrometry - Articles and news items

Webinar Feature Image

Webinar: Increasing Throughput and Sensitivity of LC-MS assays with a focus on MS optimisation and novel LC strategies

Webinars, Z Homepage promo / 13 July 2015 / Sciex

Simplifying peptide quantification with automated optimisation of MRM transitions and advantages of Micro flow LC to maximise LC-MS performance…

Chromatography 270x270

Chromatography & Mass Spec

Z Homepage promo / 22 January 2015 /

Chromatography and Mass Spectrometry are powerful techniques that have recently undergone exponential growth in their application. Explore our free-to-view article archive…

Mass-spectrometry based metabolics

Mass spectrometry-based metabolics – an exclusive online-only article from Tun-Li Shen at Brown University

Chromatography, Industry news / 3 July 2014 / Tun-Li Shen, Brown University

Tun-Li Shen provides a brief overview of the gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) instrumentation platforms used in untargeted metabolomics studies…

Mass Spectrometry In-depth focus

Mass Spectrometry: In-depth focus 2014

Chromatography, Issue 2 2014, Supplements / 15 April 2014 / Paul J. Gates, Ioannis Papayannopoulos

In this free-to-view in-depth focus: Some tricks and tools for structural characterisation of natural products using Electrospray mass spectrometry, Mass spectrometry in the biopharmaceutical industry: from the mundane to the cutting edge, and Mass Spectrometry roundtable…


Eliminate tedious sample preparation with laboratory automation from Tecan

Supplier news / 25 March 2014 / kdm communications

Tecan offers a wide range of laboratory automation solutions for mass spectrometry sample preparation, ensuring there is a system to meet your workflow and throughput needs…

Birthe V. Nielsen, Faculty of Engineering and Science, University of Greenwich

Practical considerations in analysing biologically active peptides by Electrospray Ionisation (ESI) Mass Spectrometry

Chromatography, Issue 5 2013 / 22 October 2013 / Birthe V. Nielsen, Faculty of Engineering and Science, University of Greenwich

Neuromodulators such as calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) act as biomarkers for pain assessment (pre-clinical). These markers can be detected at low concentrations by Electrospray Ionisation (ESI) Mass Spectrometry (MS). Currently, little is known about the factors affecting responsiveness in the ESI process though the response of peptide ions depends heavily on analyte basicity in solution, pKb, sampling and instrumental conditions. Other factors may be equally important, however, not enough is known about the link between peptide characteristics and selectivity in the ESI process. Here, we review our findings on these links to improve the analyte signal and allow robust quantitation of these important peptide biomarkers…

Mass Spectrometry Supplement 2013

Mass Spectrometry: In-depth focus 2013

Chromatography, Issue 2 2013, Supplements / 17 April 2013 / Uwe Christians, Jelena Klawitter, Jost Klawitter, George McLeod, Min Yang

Corticosteroids and mass spectrometry; latest applications using LC/MS3.
Multi-analyte LC-MS/MS assays for the quantification of endogenous compounds during the development of drugs and companion diagnostics…

Cancer Research UK drug launched in its first clinical trial

Future trends in drug discovery technology

Drug Discovery, Issue 6 2012 / 18 December 2012 / Terry McCann, TJM Consultancy

The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion. Herper observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of biology. While the objectives of drug discovery don’t change, the methods and techniques by which pharmaceutical companies, biotechs and academia discover new drugs are evolving at a significant pace – and they need to. Drug discovery scientists are all aiming to identify compounds and candidate drugs with ‘good’ properties that are safe and efficacious, as quickly and cheaply as possible. The standard approach of the last 20 years has been to identify a single molecule disease target, and then to identify a compound that interacts with and modulates this target with high specificity. However, there is now a growing realisation that this ‘one target – one drug’ approach doesn’t work well, and that screening huge libraries of compounds against one particular property of an isolated target is an inefficient way to discover potential drugs. Much of the innovation currently seen in drug discovery methodologies seeks to access and integrate more information – about targets, compounds, and disease phenotypes – to enable a more comprehensive and holistic approach to discovering ‘good’ drug candidates. This article does not try to crystal ball-gaze deep into the future, but rather to identify those trends in the adoption of new technologies and approaches that are gaining traction now, and that can be expected to become more prevalent in the next two to three years…

Figure 1: Sample preparation techniques for mass spectrometry based pharmaceutical and metabolite analysis. The three approaches discussed in the paper are outlined: (Top) mass spectrometry imaging from dosed tissue sections, (Middle) liquid chromatography mass spectrometry of tissue extracts or plasma/serum samples, (Bottom) gas chromatography mass spectrometry of plasma/serum samples

MS-based methods for detection, quantitation and localisation of pharmaceuticals and metabolites in biological samples

Chromatography, Issue 6 2012 / 18 December 2012 / Tyler Greer, Department of Chemistry, University of Wisconsin-Madison and Lingjun Li, Department of Chemistry & School of Pharmacy, University of Wisconsin-Madison

Mass spectrometry is a powerful, multi-faceted technique capable of analysing pharmaceuticals and their metabolites in biological matrices. Although it is more commonly applied to proteins, peptides and lipids, an increasing number of studies use mass spectrometry based techniques to detect, quantitate and localise pharmaceuticals and their metabolites. The availability of functionally unique ionisation methods and preparative separation options coupled with the specificity and sensitivity of a mass analyser make mass spectrometry an attractive option in pharmaceutical studies involving biofluids and tissue. This review aims to provide a general description of the primary mass spectrometric and preparative steps used to analyse pharmaceuticals in biological systems…

In-Depth Focus: Mass Spectrometry

In-depth focus – Mass Spectrometry

Chromatography, Issue 2 2012, Supplements / 25 April 2012 / Ana Rita Angelino, Min Yang, Tasso Miliotis, Constanze Hilgendorf, Anthony Bristow, George McLeod, Detlev Hochmuth, Alessandro Baldi, Gary Harland

Mass spectrometry in drug discovery – Proteomics, small molecules and metablomics.
Quantification of membrane drug transporters and application in drug discovery and development.
Mass spectrometry leaders roundtable.

56-59_Figure 1

Recent developments in the use of LCMS in process pharmaceutical chemistry

Chromatography, Issue 1 2012 / 28 February 2012 / Dr. Florence O. McCarthy, Department of Chemistry, Analytical and Biological Chemistry Research Facility, University College Cork

Liquid Chromatography Mass Spectrometry (LCMS) is a powerful technique that has recently undergone exponential growth in its application to pharmaceutical synthesis. This perspective will outline the general principles of LCMS, detail some recent approaches and the benefits to be derived from its use at an early stage of process development. Identification of the components in a mixture is the primary function of analytical chemistry and there are a range of techniques available. When the solution to this problem requires some structural identity, LCMS is the instrument of choice. Liquid Chromatography Mass Spectrometry is defined as the use of the separating properties of liquid chromatography combined with a detector capable of mass analysis (mass spectrometer: single quadrupole, triple quadrupole, ion trap, Time Of Flight, Q-TOF etc.). This combination may be configured in many ways, for a general scheme…

FIGURE 1 Schematic overview of the MALDI-MSI process as applied to imaging compound and metabolite distributions in a whole body rat sample. From one section of an animal dosed with the unlabelled compound, the substance and metabolite distributions can be acquired

MALDI-mass spectrometry imaging applied to drug discovery and development

Chromatography, Issue 5 2011 / 19 October 2011 / Brendan Prideaux, Dieter Staab, Gregory Morandi, Nicole Ehrhard and Markus Stoeckli, Novartis Institutes for BioMedical Research

Since its introduction in the field of biomedical imaging over 10 years ago, matrixassisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) has played an ever increasing role in drug discovery and development and is now utilised in laboratories of many leading pharmaceutical companies and collaborating academic institutions. The need for mass spectrometry imaging in drug discovery is founded on the shortcomings of current technologies. Traditional methods of spatially mapping the distribution of compounds in tissue involved a combination approach of autoradiography (WBA) with metabolite information obtained from LC/MS analysis of tissue homogenate. Autoradiography methods only monitor the radiolabel and therefore are not able to distinguish the parent drug from its metabolites. The addition of LC/MS allows for conclusive determination of metabolites. However, this only produces spatial information at the whole organ level and not the spatial detail that can be routinely achieved using MSI…

  • Page 1 of 2
  • 1
  • 2
  • >